Overview

shareholder briefcase investor kit email alerts download library snapshot news feeds Share this page
Shareholder Briefcase
Collect, save and zip multiple files for fast download and email, or bookmark your favorite files for a later visit to the IR website.
Printed Materials
Order printed documents to be sent to you by mail, or view a history of the documents you have previously requested.
Email Alerts
Fine-tune the emails you receive from Aerie Pharmaceuticals with specific SEC filing types, news types, and stock price changes. Choose to receive the closing stock price each day, or a summary of stock prices at the end of the week.
Download Library
Find exactly the file(s) you need. Send files directly into your Shareholder Briefcase, or download individual files.
Snapshot
Download a synopsis of the most recent content within our IR website.
RSS Feeds
Subscribe to RSS news feeds to automatically be notified of SEC filings and news releases.
Email this page
Email this page to yourself or a friend.
Print this page
Print a copy of this page for your records.
Search Investor Relations
Use the form below to search the investor relations site.
Share this page
Share this page with your friends using your favorite social networking site.

Stock price graph

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, dual-action AR-13324 and triple-action PG324, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.

View all »   RSSRecent News

Jul 24, 2014
Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada

Jul 23, 2014
Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014

View all »Events & Presentations

Aug 6, 2014 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. Second Quarter 2014 Earnings Call